Covid19 – AstraZeneca 80% effective against B1.617.2 variant

Covid19 - AstraZeneca 80% effective against B1.617.2 variant

Covid19 – AstraZeneca 80% effective against B1.617.2 variant

Two doses from either the Oxford/AstraZeneca or the Pfizer vaccine are over 80 per cent effective in preventing infection from the B1.617.2 variant of Covid-19, first discovered in India, a new UK government study has reportedly found. The Oxford/AstraZeneca two-dose vaccine is also being produced by the Serum Institute of India as Covishield and being administered among the adult population in India to protect against the deadly virus.

According to Indian Council of Medical Research (ICMR) head Dr Balram Bhargava, the immunity after the first dose of Covishield was found to be strong and that the three months gap will give the best results.

The UK findings are said to be based on data from Public Health England (PHE) and have also revealed that the two doses provide 87 per cent protection from the B.117 variant, first discovered in Kent region of England and also considered highly transmissible.

The Department of Health and Social Care (DHSC) has, meanwhile, said that it is ramping up testing and genome sequencing of sewage and waste water in the drive to track and trace all variants of COVID-19, including the B1.617.2 variant. A new laboratory in Exeter, south-west England, opened last month dedicated to analysing wastewater, making it one of the biggest wastewater processing labs in the world.